Last reviewed · How we verify
METHICILLIN
At a glance
| Generic name | METHICILLIN |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Linezolid Plus Standard of Care (NA)
- Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock (PHASE3)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (PHASE2)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- METHICILLIN CI brief — competitive landscape report
- METHICILLIN updates RSS · CI watch RSS